-
Repetitive transcranial magnetic stimulation for stimulant use disorders (STIMULUS): Protocol for a multi-site, double-blind, randomized controlled trial.
Atoui Z, Egan D, Jha MK, Hartwell K, Toll R, Sonne S, Brunner-Jackson B, Subramaniam G, McCauley JL, Trivedi MH, Brady KT. Repetitive transcranial magnetic stimulation for stimulant use disorders (STIMULUS): Protocol for a multi-site, double-blind, randomized controlled trial. Addiction Science & Clinical Practice 2025;20:40.
-
Impact of recent stimulant use on treatment outcomes amongst individuals initiating medications for opioid use disorders: Secondary analysis of a multisite randomized controlled trial.
Coles C, Batts C, Bae J, Leon G, Schmidt A, McPherson SM, Smith CL, Miguel AC. Impact of recent stimulant use on treatment outcomes amongst individuals initiating medications for opioid use disorders: Secondary analysis of a multisite randomized controlled trial. Drug and Alcohol Dependence Reports 2025;15:100330.
-
Exploring the impact of reduction in methamphetamine use on sexual risk behaviors among men who have sex with men and women: Findings from the ADAPT-2 trial.
Okafor CN, Yoon JH, Jean-Burluche D, Mayes TL, Shoptaw S, Trivedi MH, Potter JS, Schmitz J. Exploring the impact of reduction in methamphetamine use on sexual risk behaviors among men who have sex with men and women: Findings from the ADAPT-2 trial. International Journal of Behavioral Medicine 2025 (in press).
-
Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD).
Shulman M, Meyers-Ohki S, Novo P, Provost SE, Ohrtman K, VanVeldhuisen PC, Oden N, Otterstatter M, Bailey GL, Liu D, Rotrosen J, Weiss RD, Nunes EV. Optimizing retention strategies for opioid use disorder pharmacotherapy: The retention phase of the CTN-0100 trial (RDD). Contemporary Clinical Trials 2025;150:107816 (in press).
-
The difference-making role of staff support in implementing nurse care management for opioid use disorder treatment: A configurational analysis.
Matson TE, Lee AK, Miech EJ, Wartko PD, Phillips RC, Shea M, Altschuler A, Campbell ANC, Labell CT, Arnsten JH, Braciszewski JM, Glass JE, Horigian VE, Murphy MT, Zare-Mehrjerdi M, Bradley KA. The difference-making role of staff support in implementing nurse care management for opioid use disorder treatment: A configurational analysis. Journal of Substance Use and Addiction Treatment 2025;172:209642.
-
Predictors of participation in prenatal substance use assessment, counseling, and treatment among pregnant individuals in prenatal settings who use cannabis.
Lapham GT, Chi FW, Young-Wolff KC, Ansley D, Castellanos C, Does MB, Asyyed AH, Ettenger A, Campbell CI. Predictors of participation in prenatal substance use assessment, counseling, and treatment among pregnant individuals in prenatal settings who use cannabis. Journal of Addiction Medicine 2025;19(2):179-186.
-
Attitudes toward and experience with naloxone among people who use drugs in the southeastern United States.
Le MH, Laschober TC, Tross S, Paschen-Wolff M, Ertl MM, Wright L, Hatch MA. Attitudes toward and experience with naloxone among people who use drugs in the southeastern United States. International Journal of Drug Policy 2025;139:10479.
-
HIV prevention in syringe service programs since the start of COVID-19: Where do we go from here?
Hatch MA, Ertl M, Closs D, Keeshin S, Feinberg J, Orozco K, Tross S. HIV prevention in syringe service programs since the start of COVID-19: Where do we go from here? Current HIV/AIDS Reports 2025;22:13.
-
Effects of randomization to buprenorphine or naltrexone for oud on cannabis use outcomes: A secondary analysis of the X:BOT trial.
Shulman M, Choo T, Ohrtman K, Pavlicova M, Rotrosen J, Nunes EV. Effects of randomization to buprenorphine or naltrexone for oud on cannabis use outcomes: A secondary analysis of the X:BOT trial. Drug and Alcohol Dependence 2025;268:112550.
-
Willingness to use oral and long-acting injectable PrEP in substance-using men who have sex with men (SU-MSM) in high HIV incidence southern U.S. cities: A NIDA Clinical Trials Network study.
Tross S, Laschober TC, Paschen-Wolff M, Ertl M, Nelson CM, Wright L, Lancaster C, Feaster DJ, Monger M, Toal P, Fegley JP, Meche D, Hankey C, Woodhouse C, Spector A, Dresser L, Moran L, Jelstrom E, Haynes L, Shoptaw S, Hatch MA. Willingness to use oral and long-acting injectable PrEP in substance-using men who have sex with men (SU-MSM) in high HIV incidence southern U.S. cities: A NIDA Clinical Trials Network study. AIDS and Behavior 2025;29(4):1192-1204.